The role of cilostazol in the treatment of intermittent claudication

Current Medical Research and Opinion

Volumn 20, Issue 10, 2004, Pages 1661-1670

  Barnett, A H ^a   Bradbury, A W ^a   Brittenden, J ^b   Crichton, B ^c   Donnelly, R ^d   Homer Vanniasinkam, S ^e   Mikhailidis, D P ^f,g   Stansby, Gerard ^h,i  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c University of Aberdeen ^*

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Arterial occlusive diseases; Atherosclerosis; Cilostazol; Intermittent claudication; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTOXIFYLLINE; PLACEBO;

ALGORITHM; ANTICOAGULATION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOVASCULAR SURGERY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LIFESTYLE; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW; TREATMENT PLANNING;

EID: 7644243076     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X4464     Document Type: Review

References (66)

1. Bradbury AW. The role of cilostazol (Pletal) in the management of intermittent claudication. Int J Clin Pract 2003;57:405-9
2. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. New Engl J Med 2001;344:1608-21
3. Binnie A, Perkins J, Hands L. Exercise and nursing therapy for patients with intermittent claudication. J Clin Nursing 1999;8:190-200
4. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49
5. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1996;1:60-4
6. Davies A. The practical management of claudication. Br Med J 2000;321:911-2
7. Criqui MH. Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol 2001;88(Suppl):43J-47J
8. Burns P, Gough S, Bradbury A. Management of peripheral arterial disease in primary care. Br Med J 2003;326:584-8
9. TASC Working Group. Management of peripheral arterial disease: Transatlantic Intersociety Consensus (TASC). Eur J Vasc Endovasc Surg 2000;19(Suppl A):S1-244
10. Dormandy JA, Mahir MS. The natural history of peripheral atheromatous disease of the legs. In: Greenhalgh RM, Jamieson CW Nicolaides AN, editors. Vascular surgery: issues in current practice. London: Grune & Stratton; 1986. p. 3-17
11. Scottish Intercollegiate Guidelines Network (SIGN). Drug therapy for peripheral vascular disease. Edinburgh: Royal College of Physicians; July 1998
12. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham study. J Am Geriatr Soc 1985;33:13-8
13. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44-9
14. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. New Engl J Med 1991;324:1149-55
15. Burns P, Lima E, Bradbury AW. What constitutes best medical therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg 2002;24:6-12
16. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10
17. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand 1987;221:253-60
18. Beckmann JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. J Am Med Assoc 2002;287:2570-81
19. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333-41
20. Krentz AJ. Churchill's pocketbook of diabetes. London: Churchill Livingstone; 2003. p. 40
21. UKPDS Study Group [UKPDS 33]. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
22. UKPDS Study Group [UKPDS 34]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854-65
23. Adler AI, Stratton IM, Neil HAW, et al. on behalf of the UKPDS Study Group [UKPDS 36]. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. Br Med J 2000;321:412-9
24. UKPDS Study Group [UKPDS 38]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998;317:703-13
25. Boccalon H. Intermittent claudication in older patients. Practical treatment guidelines. Drugs Aging 1999;14:247-59
26. Collins R, Armitage J, Parish S, et al. [Heart Protection Study Collaborative Group]. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
28. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-5
29. Rubins HB, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410-18
30. Shepherd J, Cobbe SM, Ford I, et al. [West of Scotland Coronary Prevention Study Group]. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7
31. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987;317:1237-4
32. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57
33. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004;18:139-85
34. Brown MJ, Cruickshank JK, Dominiczak AF, et al., for the Executive Committee, British Hypertension Society. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6
35. Ostergren J, Sleight P, Dagenais G, et al. [HOPE study investigators]. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24
36. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31
37. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
38. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787-800
39. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Vasc Surg 2003;38:710-3
40. Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg. 2003;26:1-16
41. Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication. Is a supervised exercise class worthwhile? Br Med J 1980;280:1503-5
42. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104-15
43. Curci JA, Sanchez LA. Medical treatment of peripheral arterial disease. Curr Opin Cardiol 2003;18:425-30
44. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002;112:49-57
45. Cheetham DR, Burgess DR, Ellis M, et al. Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomised trial. Eur J Vasc Endovasc Surg 2004;27:17-23
46. Bick C. Intermittent claudication. Nursing Standard 2003;17:45-52
47. Chapman T, Goa KL. Cilostazol. A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003;3:117-38
48. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999;178:141-6
49. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial disease. Chest 1998;114:666-825
50. Perkins JM, Collin J, Creasy TS, et al. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996;11:409-13
51. Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. J Vasc Surg 1997;26:551-7
52. Bradbury AW. The management of intermittent claudication. Geriatric Med 2003;33:1-4
53. Pletal® (cilostazol) Summary of Product Characteristics
54. Pletal product monograph. Otsuka Pharmaceutical Europe Limited. January 2003
55. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314-9
56. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized multicentre study. Arch Intern Med 1999;159:2041-50
57. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87(Suppl):28-33D
58. Elam MB, Heckman MD, Crouse MD, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18:1942-7
59. Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56
60. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle culture. J Cardiovasc Pharmacol 1992;20:900-6
61. Lee TM, Su SF, Tsai CH, et al. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science 2001;101:305-11
62. Lederman RJ, Mendelsohn FO, Anderson RD, et al. [TRAFFIC Investigators]. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-8
63. Donnelly R, Yeung JM. Therapeutic angiogenesis: a step forward in intermittent claudication. Lancet 2002;359:2048-50
64. Douglas JS, Holmes D, Kereiakes D, et al. CREST Cilostazol for RESTenosis Trial. Presented at the American Heart Association's Scientific Sessions. November 9-12, 2003, Orlando, FL, USA
65. Hittel N, Donelly R. Treating peripheral arterial disease in patients with diabetes. Diabetes Obes Metab 2002;4 (Suppl 2):S26-31
66. National Heart, Lung, and Blood Institute. ATP III at-a-glance: quick desk reference. NIH Publication No. 01-3305. May 2001